• 1
    Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science. 1977;196:441444.
  • 2
    Hollenberg NK. Implications of species difference for clinical investigation: studies on the renin-angiotensin system. Hypertension. 1999;35:150154.
  • 3
    Bakhle YS, Vane JR. Pharmacokinetic function of the pulmonary circulation. Physiol Rev. 1974;54:10071045.
  • 4
    Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation. 1997;95:11151118.
  • 5
    Bock KD, Gross F. Renin and angiotensin tachyphylaxis. Circ Res. 1961;9:10441050.
  • 6
    Chansel D, Morin JP, Borghi H, et al. Angiotensin I-converting enzyme in isolated human glomeruli. FEBS Lett. 1987;220:247252.
  • 7
    Sancho J, Re R, Burton J, et al. The role of the renin-angiotensin-aldosterone system in cardiovascular homeostasis in normal human subjects. Circulation. 1976;53:400405.
  • 8
    Semplicini A, Rossi GP, Bongiovi S, et al. Time course of changes in blood pressure, aldosterone and body fluids during enalapril treatment: a double-blind randomized study vs hydrochlorothiazide plus propranolol in essential hypertension. Clin Exp Pharmacol Physiol. 1986;13:1724.
  • 9
    Sweet CS, Brody MJ. Central inhibition of reflex vasodilatation by angiotensin and reduced renal pressure. Am J Physiol. 1970;219:17511758.
  • 10
    Fink GD, Haywood JR, Bryan WJ, et al. Central site for pressor action of blood-borne angiotensin in rat. Am J Physiol. 1980;239:R358R361.
  • 11
    Bader M, Peters J, Baltatu O, et al. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J Mol Med. 2001;79:76102.
  • 12
    Re RN. The clinical implication of tissue renin angiotensin systems. Curr Opin Cardiol. 2001;16:317327.
  • 13
    Ferrario CM, Jessup J, Gallagher PE, et al. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int. 2005;68:21892196.
  • 14
    Hamming I, van Goor H, Turner AJ, et al. Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats. Exp Physiol. 2008;93:631638.
  • 15
    Urata H, Boehm KD, Philip A, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest. 1993;91:12691281.
  • 16
    Takai S, Shiota N, Jin D, et al. Functional role of chymase in angiotensin II formation in human vascular tissue. J Cardiovasc Pharmacol. 1998;32:826833.
  • 17
    Schiffrin EL, Deng LY, Larochelle P. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a beta-blocker. Am J Hypertens. 1995;8:229236.
  • 18
    Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:4146.
  • 19
    Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension. 1998;31:181188.
  • 20
    Esler M, Julius S, Zweifler A, et al. Mild high-renin essential hypertension: neurogenic human hypertension? N Engl J Med. 1977;296:405411.
  • 21
    Julius S, Krause L, Schork NJ, et al. Hyperkinetic borderline hypertension in Tecumseh, Michigan. J Hypertens. 1991;9:7784.
  • 22
    Levine TB, Francis GS, Goldsmith SR, et al. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol. 1982;49:16591666.
  • 23
    Weir MR, Chrysant SG, McCarron DA, et al. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension. 1998;31:10881096.
  • 24
    Moore TJ, Rich G, McKnight JA, et al. Salt sensitivity of hypertension and responses to angiotensin converting enzyme inhibition with benazepril. Am J Hypertens. 1996;9:5460.
  • 25
    Dluhy RG, Smith K, Taylor T, et al. Prolonged converting enzyme inhibition in non-modulating hypertension. Hypertension. 1989;13:371377.
  • 26
    Weidmann P, Beretta-Piccoli C, Ziegler WH, et al. Age versus urinary sodium for judging renin, aldosterone, and catecholamine levels: studies in normal subjects and patients with essential hypertension. Kidney Int. 1978;14:619632.
  • 27
    Cooper WD, Glover DR, Kimber GR. Influence of age on blood pressure response to enalapril. Gerontology. 1987;33(suppl 1):4854.
  • 28
    Chrysant SG, Danisa K, Kem DC, et al. Racial differences in pressure, volume and renin interrelationships in essential hypertension. Hypertension. 1979;1:136141.
  • 29
    Blood pressure guidelines – where are we now? Drug Ther Bull. 2008;46:6569.
  • 30
    Mayer G. ACE genotype and ACE inhibitor response in kidney disease: a perspective. Am J Kidney Dis. 2002;40:227235.
  • 31
    Ruggenenti P, Perna A, Zoccali C, et al. Chronic proteinuric nephropathies II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (GISEN). J Am Soc Nephrol. 2000;11:8896.
  • 32
    Gharavi AG, Lipkowitz MS, Diamond JA, et al. Deletion polymorphism of the angiotensin-converting enzyme gene is independently associated with left ventricular mass and geometric remodeling in systemic hypertension. Am J Cardiol. 1996;77:13151319.
  • 33
    Ruggenenti P, Bettinaglio P, Pinares F, et al. Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin J Am Soc Nephrol: CJASN. 2008;3:15111525.
  • 34
    ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:29812997.
  • 35
    Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:28052816.
  • 36
    Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895906.
  • 37
    Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study. N Engl J Med. 2000;342:145153.
  • 38
    Svensson P, de Faire U, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension. 2001;38:E28E32.
  • 39
    Pfeffer MA, Braunwald E, Moyé LA. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669677.
  • 40
    Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342:821828.
  • 41
    Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:16701676.
  • 42
    Ambrosioni E, Borghi C, Magnani B, et al. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995;332:8085.
  • 43
    Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:15751581.
  • 44
    Gruppo GISSI 3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343:11151122.
  • 45
    Fourth International Study of Infarct Survival (ISIS-4). A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Fourth International Study of Infarct Survival (ISIS-4). Lancet. 1995;345:669685.
  • 46
    Chinese Collaborative Study Coordinating Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CC-1). Lancet. 1995;345:686687.
  • 47
    Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110:e82e292.
  • 48
    Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:13851390.
  • 49
    Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:15821587.
  • 50
    Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360:752760.
  • 51
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:18931906.
  • 52
    CONSENSUS Trial Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:14291435.
  • 53
    SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293302.
  • 54
    SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:68591.
  • 55
    Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet. 2003;361:18431848.
  • 56
    Cohn JN, Johnson GA, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303310.
  • 57
    Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:23382345.
  • 58
    Zatz R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986;77:19251930.
  • 59
    Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:14561462.
  • 60
    Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Int Medicine. 2003;139:244252.
  • 61
    Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361:4051.
  • 62
    Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Eng J Med. 1994;330:877884.
  • 63
    Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939946.
  • 64
    Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. [see comment]. JAMA. 2001;285:27192728.
  • 65
    Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:24212431.
  • 66
    Appel LJ, Wright JT Jr, Greene T, et al. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Int Med. 2008;168:832839.
  • 67
    Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354:131140.
  • 68
    Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:10331041.
  • 69
    Arima H, Chalmers J, Woodward M, et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens. 2006;24:12011208.
  • 70
    Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Int Med. 2003;163:10691075.
  • 71
    Bavry AA, Anderson RD, Gong Y, et al. Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension. 2010;55:4853.
  • 72
    Ferguson RK, Turini GA, Brunner HR, et al. A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet. 1977;1:775778.
  • 73
    Kawamura M, Imanishi M, Matsushima Y, et al. A comparison of lisinopril with enalapril by monitoring plasma angiotensin II levels in humans. Jpn J Pharmacol. 1990;54:143149.
  • 74
    Luzier AB, Navsarikar A, Wilson M, et al. Physician prescribing patterns of ACE inhibitors in secondary prevention post myocardial infarction. Pharmacotherapy. 1999;19:655660.
  • 75
    Luzier AB, Forrest A, Adelman M, et al. Impact of angiotensin-converting enzyme inhibitors underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol. 1998;82:465469.
  • 76
    Luzier AB, Forrest A, Feuerstein SG, et al. Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization. Am J Cardiol. 2000;86:519523.
  • 77
    Biollaz J, Brunner HR, Gavras I, et al. Antihypertensive therapy with MK 421: angiotensin II – renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982;4:966972.
  • 78
    Izzo JL Jr, Weinberg MS, Hainer JW, et al. Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials. J Clin Hypertens. 2004;6:485493.
  • 79
    Yusuf S, Teo KK, Pogue J,et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15471559.
  • 80
    Matthews PG, McGrath BP, Johnston CI. Hormonal changes with long-term converting-enzyme inhibition by captopril in essential hypertension. Clin Sci. 1979;57(suppl 5):135s138s.
  • 81
    Nussberger J, Waeber B, Brunner HR. Clinical pharmacology of ACE inhibition. Cardiol. 1989;76(suppl 2):1122.
  • 82
    Grassi G, Cattaneo BM, Seravalle G, et al. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation. 1997;96:11731179.
  • 83
    Ahmed A. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine? J Am Geriatrics Soc. 2002;50:12971300.
  • 84
    Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Int Med. 2000;160:685693.
  • 85
    Deary AJ, Schumann AL, Murfet H, et al. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens. 2002;20:771777.
  • 86
    Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25:17511762.
  • 87
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: JNC 7 Express. JAMA. 2003;289:25602572.
  • 88
    Mann JFE, Schmieder RE, Dyal L, et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Internal Med. 2009;151:110.
  • 89
    McMurray JJV, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767771.
  • 90
    McMurray JJV, Young JB, Dunlap ME, et al. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: assessment of reduction in mortality and morbidity (CHARM)-added trial. Am Heart J. 2006;151:985991.
  • 91
    Catapano F, Chiodini P, De Nicola L, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis. 2008;52:475485.
  • 92
    Gradman AH, Basile JN, Carter BL, Bakris GL, American Society of Hypertension Writing Group. Combination therapy in hypertension. J Am Soc Hyperten. 2010;4:4250.